ENTX_OUT_1 [2025-04-02 18:20:24 -0400] 2363 Bytes | 667 tokens | Cum: 667 tkns (8.34% of 8k)
==========================================================================

We need a winner today and it's already 6:20:23 PM on Wed Apr 02, 2025 -0400 ... So let's find out if Entera Bio (ENTX) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 1.91 up from 1.63. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Entera Bio (ENTX)
IPO: IPO date unknown
Shares Outstanding: 45,420,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS

Here's the first list of news for Entera Bio:

C1 - Mar-28-25 04:05PM - Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
C2 - Mar-18-25 11:37AM - Opko and Entera focus on oral care for obesity and metabolic disorders
C3 - Mar-17-25 08:00AM - OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
C4 - Feb-24-25 08:30AM - Entera Bio to Participate in Upcoming Events
C5 - Feb-19-25 08:00AM - EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
C6 - Jan-27-25 08:00AM - Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
C7 - Nov-08-24 05:15PM - Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
C8 - Nov-08-24 05:15PM 04:05PM - Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Entera Bio (ENTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ENTX_OUT_3 [2025-04-02 18:20:30 -0400] 1102 Bytes | 321 tokens | Cum: 990 tkns (12.38% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates**
Date: Mar-28-25 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/28/3051629/0/en/Entera-Bio-Announces-Full-Year-2024-Financial-Results-and-Provides-Business-Updates.html

March 28, 2025 16:05 ET| Source:Entera Bio Ltd.Entera Bio Ltd.

JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.

“2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1-34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently strengthened our balance sheet. To

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ENTX_OUT_5 [2025-04-02 18:20:31 -0400] 923 Bytes | 263 tokens | Cum: 1351 tkns (16.89% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T21:24:16Z - Opko health CEO Phillip Frost buys $164,850 in stock By Investing.com...
A2 - 2025-03-29T20:49:24Z - Entera Bio (NASDAQ:ENTX) Issues Earnings Results...
A3 - 2025-03-28T20:43:20Z - Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates | Taiwan News | ...
A4 - 2025-03-28T20:05:00Z - Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates...
A5 - 2025-03-28T20:06:49Z - Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ENTX_OUT_7 [2025-04-02 18:20:35 -0400] 1098 Bytes | 303 tokens | Cum: 1656 tkns (20.70% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Opko health CEO Phillip Frost buys $164,850 in stock By Investing.com**Date: 2025-04-01Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/insider-trading-news/opko-health-ceo-phillip-frost-buys-164850-in-stock-93CH-3961575Phillip Frost, CEO and Chairman of OPKO Health, Inc. (NASDAQ:OPK), has recently increased his stake in the company. According to a filing with the Securities and Exchange Commission, Frost acquired 100,000 shares of common stock on April 1, 2025, with the purchase price averaging $1.6485 per share. This transaction amounted to a total of $164,850. The purchase price aligns closely with the current market value of $1.66, with the stock trading near InvestingPro's calculated Fair Value. The company maintains a healthy liquidity position with a current ratio of 3.43.

The shares were purchased by Frost Ga

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ENTX_OUT_9 [2025-04-02 18:20:36 -0400] 920 Bytes | 307 tokens | Cum: 2059 tkns (25.74% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-17T12:00:00Z - OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
B2 - 2024-06-03T14:05:00Z - AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
B3 - 2024-06-03T13:40:09Z - Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?
B4 - 2024-05-31T14:36:00Z - Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
B5 - 2024-05-30T15:29:00Z - Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
B6 - 2024-05-29T14:51:00Z - AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ENTX_OUT_11 [2025-04-02 18:20:40 -0400] 856 Bytes | 246 tokens | Cum: 2307 tkns (28.84% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/17/3043620/0/en/OPKO-Health-and-Entera-Bio-Enter-into-Collaboration-Agreement-to-Advance-Oral-GLP-1-Glucagon-Tablet-Candidate-into-the-Clinic-to-Treat-Obesity-and-Metabolic-Disorders.htmlOPKO Health and Entera Bio have entered into a collaboration agreement to advance an oral GLP-1/Glucagon dual agonist tablet into clinical trials for the treatment of obesity and metabolic disorders.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ENTX_OUT_13 [2025-04-02 18:20:40 -0400] 1044 Bytes | 290 tokens | Cum: 2661 tkns (33.26% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-28 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

##TABLE_END

This Annual Report contains forward-looking statements within the meaning of the PSLRA, Section 27A of the Securities Act, and Section 21E of the Exchange Act, about our ...

S2 - 2025-03-17 8-K Item 1.01 Entry into a Material Definitive Agrmt

On March 16, 2025 (the Effective Date ), Entera Bio Ltd., a company organized under the laws of the State of Israel (the Company ), entered into collaboration and license agreement (the Collaboration Agrmt ) with OPKO Heal...

S8 - 2024-11-08 10-Q ITEM 1. FIN STATEMENTS

ENTERA BIO LTD.

UNAUDITED COND

CONS FIN STATEMENTS

AS OF SEPTEMBER 30, 2024

Page

COND CONS FIN STATEMENTS:

Condensed Cons Balance Sheets (unaudited)

Condensed Cons Stmnts of ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ENTX_OUT_15 [2025-04-02 18:20:44 -0400] 1098 Bytes | 280 tokens | Cum: 2943 tkns (36.79% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 1.01 Entry into a Material Definitive Agreement

On March 16, 2025 (the Effective Date ), Entera Bio Ltd., a company organized under the laws of the State of Israel (the Company ), entered into collaboration and license agreement (the Collaboration Agreement ) with OPKO Health, Inc., a Delaware corporation ( OPKO Health ), and OPKO Biologics Ltd., a company organized under the laws of the State of Israel ( OPKO Biologics and, together with OPKO Health, OPKO ), to collaborate with respect to the preclinical and clinical development and decision making related to the oral delivery of a dual agonist GLP-1/glucagon peptide in an oral dosage form using Enteras N-Tab technology platform for the treatment of obesity, metabolic and fibrotic disorders in humans (the Program ). The Program combines OPKOs proprietary long-acting oxyntomodulin (OXM, dual targeted GLP-1/Glucagon agonist, OPK

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ENTX_OUT_17 [2025-04-02 18:20:53 -0400] 6649 Bytes | 1883 tokens | Cum: 4923 tkns (61.54% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+------------------------+
| Volume: 19,817 | Perf Month: -15.15% | Option/Short: Yes / Yes | Sales Y/Y TTM: 607.14% |
+---------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 118.13K | Perf Quarter: -22.94% | Short Float: 0.24% | ROE: -103.34% |
+---------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 0.17 | Index: - | Short Ratio: 0.73 | ROI: -116.61% |
+---------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 35.05 | Market Cap: 76.31M | Short Interest: 0.09M | Sales Surprise: 0.00% |
+---------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 0.13 | Shs Outstand: 38.84M | Beta: 1.56 | EPS Surprise: 25.00% |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA20: -9.78% | Shs Float: 36.62M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA50: -19.71% | Inst Own: 22.48% | Sales past 5Y: -13.09% | Earnings: Mar 28 AMC |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA200: -13.14% | Insider Own: 19.38% | Employees: 20 | |
+---------------------+-----------------------+-------------------------+------------------------+
| Perf Week: -7.44% | Insider Trans: 0.00% | Debt/Eq: 0.03 | |
+---------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Entera Bio Ltd. (ENTX) by Ellis Sean (Unknown Title) on 2025-01-15
- Ordinary Shares, par value NIS 0.0000769 per share: 7100 shares at $0 (D) Footnote: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.
- Stock Option (right to buy): 28509 shares at $0 (D)

Inside Trans: Entera Bio Ltd. (ENTX) by LIEBERMAN GERALD M (Unknown Title) on 2025-01-15
- Ordinary Shares, par value NIS 0.0000769 per share: 10717 shares at $0 (D) Footnote: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.
- Stock Option (right to buy): 28509 shares at $0 (D)

Inside Trans: Entera Bio Ltd. (ENTX) by Malca Yonatan (Unknown Title) on 2025-01-15
- Ordinary Shares, par value NIS 0.0000769 per share: 8216 shares at $0 (D) Footnote: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.
- Stock Option (right to buy): 28509 shares at $0 (D)

Inside Trans: Entera Bio Ltd. (ENTX) by OSTROV GERALD M (Unknown Title) on 2025-01-15
- Ordinary Shares, par value NIS 0.0000769 per share: 8038 shares at $0 (D) Footnote: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.
- Stock Option (right to buy): 28509 shares at $0 (D)

Inside Trans: Entera Bio Ltd. (ENTX) by Taitel Haya (Unknown Title) on 2025-01-15
- Ordinary Shares, par value NIS 0.0000769 per share: 6922 shares at $0 (D) Footnote: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.
- Stock Option (right to buy): 28509 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 181000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -9541000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.68
Average Volume: 51550.48
30-Day High: 2.06
30-Day Low: 1.63

[Detailed Financials: TTM 2024]
- Total Assets: $9,390,000.0
- Total Liabilities: $1,310,000.0
- Total Equity: $8,080,000.0
- Current Assets: $8,972,000.0
- Current Liabilities: $1,176,000.0

[Income Statement: TTM 2024]
- Revenue: $181,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.25

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-2,345,000.0

[Detailed Financials: FY 2024]
- Total Assets: $9,390,000.0
- Total Liabilities: $1,310,000.0
- Total Equity: $8,080,000.0
- Current Assets: $8,972,000.0
- Current Liabilities: $1,176,000.0

[Income Statement: FY 2024]
- Revenue: $181,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.25

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-2,345,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ENTX_OUT_19 [2025-04-02 18:20:58 -0400] 676 Bytes | 167 tokens | Cum: 5354 tkns (66.92% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ENTX_IN_21 [2025-04-02 18:20:58 -0400] 126 Bytes | 29 tokens | Cum: 5483 tkns (68.54% of 8k)
==========================================================================

====================================
[2025-04-02 18:20:58] # Analysis Completed
Elapsed Time: 35.18 seconds